Optimization of left bundle area pacing using a novel electrocardiogram device Authors: Paishiun Nelson Hsieh, David E. Albert, Kim Barnett, Eugene H. Chung Published: 2026 Key Teaching Points •A portable reduced-lead ECG can generate a 12-lead ECG•Conduction system pacing can be achieved using reduced-lead ECG device comparable to conventional ECG recording systems•This may democratize conduction system pacing and improve procedural success in settings outside of the EP lab Key Teaching Points •A portable reduced-lead ECG can generate a 12-lead ECG•Conduction system pacing can be achieved using reduced-lead ECG device comparable to conventional ECG recording systems•This may democratize conduction system pacing and improve procedural success in settings outside of the EP lab •A portable reduced-lead ECG can generate a 12-lead ECG A portable reduced-lead ECG can generate a 12-lead ECG •Conduction system pacing can be achieved using reduced-lead ECG device comparable to conventional ECG recording systems Conduction system pacing can be achieved using reduced-lead ECG device comparable to conventional ECG recording systems •This may democratize conduction system pacing and improve procedural success in settings outside of the EP lab This may democratize conduction system pacing and improve procedural success in settings outside of the EP lab Introduction Chronic right ventricular (RV) pacing can be harmful, leading to pacing-induced cardiomyopathy in 20% of patients.1 Conduction system pacing (CSP), with an initial focus on the His bundle, may reduce cardiovascular risk while allowing a high burden of pacing.1 In this context, left bundle branch area pacing (LBBAP) has attracted renewed interest. Successful LBBAP is determined by examining specific electrocardiographic (ECG) criteria including a paced QRS morphology, stimulation to left ventricular activation time (LVAT), V6 R-wave peak time (RWPT), and V6–V1 peak-to-peak interval.2 Currently, an electrophysiology (EP) laboratory recording system is used in real time to measure validated metrics during lead implantation. In this case, we present the novel use of a pocketable, smart device–based, reduced-lead ECG system, which may simplify the measurement of these metrics outside of the EP laboratory and enable CSP assessment in a postprocedural or outpatient setting and in under-resourced regions without EP recording systems. History of presentation We report the case of a 63-year-old male patient with hereditary Charcot-Marie-Tooth disease with mild atrophy undergoing evaluation for dyspnea on exertion who was ultimately diagnosed on a cardiopulmonary exercise test as having chronotropic incompetence. His cardiopulmonary exercise test revealed sinus rhythm with a normal QRS (QRS 92 ms) but he was only able to reach a heart rate of 90 beats per minute at peak effort (as determined by a respiratory exchange ratio of >1.1). There were no ECG signs of ischemia with exertion. On his wearable watch, he self-reported a maximum heart rate of approximately 80 beats per minute. We subsequently recommended implantation of a dual-chamber permanent pacemaker (PPM), and for the RV lead, we recommended using an LBBAP lead. The procedure was performed in an EP laboratory using a GE Cardiolab (GE HealthCare, Waukesha, WI) to measure the intervals used to optimize the location of the LBBA lead in the intraventricular septum. In addition to the EP laboratory recording system, the necessary intervals were measured with the patient’s permission using a novel, portable reduced-lead 12-lead ECG, the Kardia 12L (AliveCor, Mountain View, CA) during the case and analyzed in detail after the case. The implantation of a Boston Scientific ACCOLADE dual-chamber pacemaker including the 7842 Ingevity+ magnetic resonance imaging lead for LBBAP went smoothly without complications. The important intervals from the Cardiolab and Kardia 12L were compared. A screen capture from the Cardiolab showing the manual cursor placements on the 12-lead ECG data at the QRS onset and offset, at the pacemaker stim artifact, at the peak of the R wave in V6, and at the peak of the r’ wave in V1 is presented in Figure 1A. These marks allow the displayed calculation of the QRS duration (QRSD), V6RWPT, and V1RWPT. From these last 2 intervals, the V6–V1 interpeak interval was manually calculated.Figure 1A: GE Cardiolab screen capture. Calipers defining the important intervals. B: Kardia 12L median beat screen. Manually adjusted calipers showing the important intervals and calculating the metrics. C: Kardia 12L median beat screen. Showing the RWPT for lead I to calculate the “Global” RWPT. A: GE Cardiolab screen capture. Calipers defining the important intervals. B: Kardia 12L median beat screen. Manually adjusted calipers showing the important intervals and calculating the metrics. C: Kardia 12L median beat screen. Showing the RWPT for lead I to calculate the “Global” RWPT. The median beat measurement screen of the Kardia 12L is presented in Figure 1B. The same ECG locations as those on the Cardiolab were automatically located. If necessary, the operator can manually adjust those locations with movable calipers. The QRSD, the LVAT (same as the V6RWPT), the V1R (same as the V1RWPT), and the V6–V1 (V6–V1 interpeak interval) are automatically calculated and displayed. Finally, the measurement of the lead I RWPT, which is summed with the V6RWPT to calculate a “Global” RWPT (see discussion for explanation), is presented in Figure 1C. The Kardia 12L module, the single-lead wire, and the V6 lead extension are presented in Figure 2A. In addition to the standard Kardia 12L, the CSP application includes a lead extension so that the normal V4 electrode connection can be located at the V6 position. This module communicates with smart devices using Bluetooth to record and transmit the ECG data in real time. The locations of the electrode positions along the Kardia 12L single-lead wire are presented in Figure 2B. Those locations included LL, LA, V6, V1, and RA.Figure 2A: Kardia 12L. Artificial intelligence–powered, reduced-lead diagnostic electrocardiogram with a single-electrode cable design and the V6 lead extender. The pocketable pod communicates via Bluetooth with a smartphone or tablet to record, interpret, and transmit high-quality electrocardiogram leads. B: Kardia 12L on a patient. Novel 5-electrode cable design connected to LL, LA, V6, V1, and RA to provide leads I, II, III, aVR, aVL, aVF, V1, and V6. A: Kardia 12L. Artificial intelligence–powered, reduced-lead diagnostic electrocardiogram with a single-electrode cable design and the V6 lead extender. The pocketable pod communicates via Bluetooth with a smartphone or tablet to record, interpret, and transmit high-quality electrocardiogram leads. B: Kardia 12L on a patient. Novel 5-electrode cable design connected to LL, LA, V6, V1, and RA to provide leads I, II, III, aVR, aVL, aVF, V1, and V6. Finally, a comparison of the metrics used to optimize the LBBAP between the Cardiolab and the Kardia 12L is presented in Table 1. The values are insignificantly different, and both sets of values fall into the ranges for left bundle branch (LBB) capture.Table 1Correlation of LBBAP metrics between Cardiolab and Kardia 12LModalityLVATQRSDV6–V1 intervalV1RWPTV6 + I RWPTCardiolab74 ms110 ms43 ms117 ms156 msKardia 12L75 ms105 ms44 ms120 ms160 msLBBAP, left bundle branch area pacing; LVAT = left ventricular activation time; QRSD = QRS duration; RWPT = R-wave peak time. Table 1Correlation of LBBAP metrics between Cardiolab and Kardia 12LModalityLVATQRSDV6–V1 intervalV1RWPTV6 + I RWPTCardiolab74 ms110 ms43 ms117 ms156 msKardia 12L75 ms105 ms44 ms120 ms160 msLBBAP, left bundle branch area pacing; LVAT = left ventricular activation time; QRSD = QRS duration; RWPT = R-wave peak time. Correlation of LBBAP metrics between Cardiolab and Kardia 12L LBBAP, left bundle branch area pacing; LVAT = left ventricular activation time; QRSD = QRS duration; RWPT = R-wave peak time. Discussion The last several years have seen an accelerating adoption of LBBAP to avoid adverse cardiovascular outcomes from chronic pacing after PPM implantation. The Heart Rhythm Society provided guidelines on CSP for the avoidance of heart failure in 2023.1 However, proper positioning and fixation of the LBBA lead present challenges to the operator and require careful measurement of various ECG features to distinguish septal pacing from nonselective LBB pacing and selective LBB pacing. In settings without access to an EP laboratory recording system (eg, operating rooms, ambulatory centers, under-resourced regions), optimization of lead position may be limited to fluoroscopic guidance. Compared with other modalities, the Kardia 12L not only provides all the measurements that have been used for LBBAP optimization but can also do these in real time and automatically, all in a pocketable format of a small device, single-lead wire, and tablet computer (Table 2).Table 2Modalities for the assessment of LBBAPModalityProsConsStandard 12-lead ECG•Widely available in most clinical settings•Familiar with clinical staff•Inability to quantitatively measure parameters•Requires additional cumbersome leads in a sterile field•Sweep speeds typically limitedEP laboratory recording system•High-fidelity, multichannel recording•Live, digital calipers with sweep speeds of up to 200 mm/s•Convenient review and scrolling•High cost•Requires expert EP staff and trained technicians•Not portableCatheterization laboratory hemodynamic system (eg, Mac-Lab)•Available in standard catheterization laboratories or operating rooms•Continuous monitoring for review•Inconvenient user interface for telemetry•Difficult to use in real timeCIED programmer (PSA)•Equipment already present during implant•Displays real-time intracardiac electrograms•Often displays a limited number of leads•Screen size and caliper functions not optimized for precise measurementsKardia 12L•Highly portable and pocketable•High resolution (1000 Hz) and sweep speeds of up to 200 mm/s•User-adjustable calipers and automatic calculation of LBBAP parameters•Single cable design•Must be integrated into implant workflow•Uses surface leads, no intracardiac recordingsCIED = cardiac implantable electronic device; ECG = electrocardiogram; EP = electrophysiology; LBBAP = left bundle branch area pacing; PSA = pacing system analyzer. Table 2Modalities for the assessment of LBBAPModalityProsConsStandard 12-lead ECG•Widely available in most clinical settings•Familiar with clinical staff•Inability to quantitatively measure parameters•Requires additional cumbersome leads in a sterile field•Sweep speeds typically limitedEP laboratory recording system•High-fidelity, multichannel recording•Live, digital calipers with sweep speeds of up to 200 mm/s•Convenient review and scrolling•High cost•Requires expert EP staff and trained technicians•Not portableCatheterization laboratory hemodynamic system (eg, Mac-Lab)•Available in standard catheterization laboratories or operating rooms•Continuous monitoring for review•Inconvenient user interface for telemetry•Difficult to use in real timeCIED programmer (PSA)•Equipment already present during implant•Displays real-time intracardiac electrograms•Often displays a limited number of leads•Screen size and caliper functions not optimized for precise measurementsKardia 12L•Highly portable and pocketable•High resolution (1000 Hz) and sweep speeds of up to 200 mm/s•User-adjustable calipers and automatic calculation of LBBAP parameters•Single cable design•Must be integrated into implant workflow•Uses surface leads, no intracardiac recordingsCIED = cardiac implantable electronic device; ECG = electrocardiogram; EP = electrophysiology; LBBAP = left bundle branch area pacing; PSA = pacing system analyzer. Modalities for the assessment of LBBAP •Widely available in most clinical settings Widely available in most clinical settings •Familiar with clinical staff Familiar with clinical staff •Inability to quantitatively measure parameters Inability to quantitatively measure parameters •Requires additional cumbersome leads in a sterile field Requires additional cumbersome leads in a sterile field •Sweep speeds typically limited Sweep speeds typically limited •High-fidelity, multichannel recording High-fidelity, multichannel recording •Live, digital calipers with sweep speeds of up to 200 mm/s Live, digital calipers with sweep speeds of up to 200 mm/s •Convenient review and scrolling Convenient review and scrolling •High cost High cost •Requires expert EP staff and trained technicians Requires expert EP staff and trained technicians •Not portable Not portable •Available in standard catheterization laboratories or operating rooms Available in standard catheterization laboratories or operating rooms •Continuous monitoring for review Continuous monitoring for review •Inconvenient user interface for telemetry Inconvenient user interface for telemetry •Difficult to use in real time Difficult to use in real time •Equipment already present during implant Equipment already present during implant •Displays real-time intracardiac electrograms Displays real-time intracardiac electrograms •Often displays a limited number of leads Often displays a limited number of leads •Screen size and caliper functions not optimized for precise measurements Screen size and caliper functions not optimized for precise measurements •Highly portable and pocketable Highly portable and pocketable •High resolution (1000 Hz) and sweep speeds of up to 200 mm/s High resolution (1000 Hz) and sweep speeds of up to 200 mm/s •User-adjustable calipers and automatic calculation of LBBAP parameters User-adjustable calipers and automatic calculation of LBBAP parameters •Single cable design Single cable design •Must be integrated into implant workflow Must be integrated into implant workflow •Uses surface leads, no intracardiac recordings Uses surface leads, no intracardiac recordings CIED = cardiac implantable electronic device; ECG = electrocardiogram; EP = electrophysiology; LBBAP = left bundle branch area pacing; PSA = pacing system analyzer. For CSP, it is critical to ensure the nonselective or selective capture of the LBB as opposed to the intraventricular septum. Because of this, several ECG-based metrics have been developed with interval criteria for differentiating the site of capture. Given that the LBB runs along the left ventricular (LV) endocardial side of the septum, advancement of a pacing lead from the RV can be a tedious and difficult process. Finally, the conduction velocities, capture thresholds, and refractoriness between the conduction system and cardiac myocardium enable the use of depolarization intervals from the surface ECG to identify the capture location. LBB capture provides faster and more homogeneous depolarization of the LV than septal myocardial capture. The initial investigators used V6RWPT (also called the LVAT) to identify LBB capture.2 This interval is the time from the pacemaker stimulus to the peak of the R wave in V6, representing the time it takes the depolarization wave to reach the lateral LV wall.3 Jastrzębski et al4,5 proposed a V6RWPT cutoff of less than 83 ms for LBB capture with a sensitivity of 84.7% and a specificity of 96.3%. The V6–V1 interpeak interval is also used to discriminate among septal capture, nonselective LBB capture, and selective LBB capture.6 This metric overcomes ambiguity in measurement from the pacing stimulus (owing to pacing latency or intraventricular conduction delay), given that the presence of an isoelectric interval between stimulus artifact and LV capture is variably dependent on sweep speed. Given that the isoelectric latency period is often not apparent at 25 mm/s speeds, some authors advocate for measuring from the end of the stimulus artifact for true conduction time, rather than from the onset of the pacing stimulus.7,8 Rijks et al9 have additionally suggested different thresholds for the V6–V1 interpeak interval than specified in the original paper to better localize the LBB lead position. Additional groups have proposed combinations of various intervals as superior.10 In 2025, Kiełbasa et al11 proposed using a “global” RWPT that combines RWPTs from leads I and V6. Zhuo et al12 used dynamic changes in the S wave in V6 as an indicator of LBB capture. Other groups have attempted to use a standard 12-lead ECG machine to help in the optimization of LBB lead location.13 Whichever existing or future ECG metric of LBB capture becomes the standard, a significant barrier to global utilization of this procedure exists. All the described intervals and combinations require a high-resolution, multichannel EP laboratory recording system, which only exists in EP laboratories. These recording systems have capabilities unavailable in current 12-lead ECG machines including real-time scrolling and screen freeze with sweep speeds of 100–200 mm/s, gain of up to 40 mm/mV, adjustable filtering, and calipers. The lack of an EP laboratory recording system in settings including outpatient surgical centers, PPM clinics, or operating rooms and in under-resourced regions worldwide makes the optimization of CSP difficult if not impossible. The Kardia 12L is a reduced-lead, pocketable 12-lead diagnostic ECG system that uses a high-resolution ECG acquisition pod and a single-electrode cable design and transmits real-time ECG data to a smartphone or tablet computer for display and processing. The data are high resolution at 1000 samples per second and 24-bit resolution. For the CSP application, the Kardia 12L records leads I, II, V1, and V6 providing leads I, II, III, aVR, aVL, aVF, V1, and V6. The Kardia 12L at present does not replace the continuous, multichannel, high-speed monitoring of a standard EP laboratory recording system. However, all current metrics can be measured and calculated from these leads and correlated well in our case. The Kardia 12L captures a multibeat median complex and performs automatic identification of the relevant fiducial points (pacing stimulus, QRS onset, QRS offset, and RWPT for all leads). This enables the automatic calculation and display of QRSD, LVAT (same as V6RWPT), V1 RWPT, and the V6–V1 interpeak interval. The automatically defined fiducial points can be user modified with calipers, and the display can show up to 200 mm/s and 40 mm/mV to enable precise measurements. Conclusion This case describes the first-in-human use of a portable Kardia 12L device to assess the implantation of an LBBA pacemaker. The Kardia 12L metrics (automatic and manually defined) correlated highly with measurements made on a GE Cardiolab system. That comparison is presented in Table 1. In addition to the intervals presented in Figure 1A and 1B, the “global” RWPT was similar in both systems, which is defined as the sum of RWPT in leads I and V6. Our case suggests that the Kardia 12L has the potential to serve as an alternative (currently off-label) in resource-limited settings to confirm CSP in pacemaker clinics, surgical centers, and under-resourced regions. Prospective studies are necessary and ongoing to assess its precision and accuracy in this context. Disclosures Dr Albert is the founder and chief medical officer of AliveCor. He is a member of the board of directors. He receives a significant salary from AliveCor and is an equity holder in AliveCor. Mr Barnett receives a salary (significant) and has equity in AliveCor. Drs Hsieh and Chung have no relevant disclosures for this case report.